These theoretical particles ignore the basic structure of cause and effect, leading to some pretty absurd situations.
Microsoft appears to be seriously considering small modular nuclear reactors to help supply the power needs for its AI program.
Would hope this means we dont Need to reverse engineer and are done w/ the brains of insects. From here, id like to see done in about following order, reverse engineer brains of: 1. Mice, 2. Lab Rats, 3. Crows (small brains, but supposedly smarter than chimps) 4. Octopi, 5. Pigs, 6. Chimps, and 7. and end on the human brain. Would hope we can do work on each in the build up to human brains, mainly tec it will require to reverse engineer all mentioned. Maybe it leads no where, or maybe we need it all to solve Agi. Also, aim for completion by 12/31/2029. Wanted to add, i believe should be an international effort: US, Canada, EU, Israel, Korea, Japan, etc… instead of just being a US project.
By Anne J. Manning Harvard Staff Writer.
Date September 26, 2023 September 27, 2023.
Continue reading “Human brain too big to map so they’re starting with mice” »
Scientists have captured the fleeting moment when a heart starts beating, a feat made all the more remarkable when you consider the relative brevity of a zebrafish’s life.
In a tight window about 20 hours into zebrafish development, the embryos’ developing hearts jumped into action, emerging as one from an ensemble of single cells.
“It was like somebody had flipped on a switch,” says Harvard University biophysicist Adam Cohen, senior author of the new study, which imaged zebrafish embryos snug in custom-made agarose molds to capture this once-in-a-lifetime event.
Scientists removed the outer lid of OSIRIS-REx’s sample canister on Tuesday (Sept. 26). But a full reveal of the mission’s asteroid sample is still two weeks away.
Using their new scaffold with cryo-EM, the UCLA-led team saw the atomic structure of KRAS when it was connected to a drug being studied for lung cancer treatment. This showed that their method can help understand how drugs interact with proteins like KRAS, potentially leading to better medicines.
Castells-Graells said, “The potential applications for the new advance don’t stop with cancer drugs. ” Our modular scaffold can be assembled in any configuration to capture and hold all small protein molecules.”
The UCLA-led team’s essential improvement to cryo-EM technology represents a significant milestone in structural biology and scientific imaging. Their achievement in visualizing small therapeutic protein targets at 3 Å resolution is a testament to the power of innovation and collaboration in pushing the boundaries of scientific discovery. This breakthrough promises to revolutionize drug development and our understanding of complex biological systems, further solidifying Cryo-EM’s place as an invaluable tool in modern research.
https://www.youtube.com/watch?v=6LoTCc185dE
Zuby Interviews Elon Musk: https://youtu.be/pjc_oo4ApSY?si=AHD8kdwXqmB1wrjpNeura Pod is a series covering topics related to Neuralink, Inc. Topics such as br…
Early detection of illnesses such as prostate cancer is key to treatment and a possible cure. Find out what you need to know and why you shouldn’t wait.
How well that translation occurs remains to be seen while the patient learns and adapts to the new system. “The implant procedures involving the Onward ARC-IM and Clinatec BCI went smoothly,” Dr. Bloch said in an press release. “We are now working with the patient to use this cutting-edge innovation to recover movement of his arms, hands, and fingers. We look forward to sharing more information in due course.”
“If the therapy continues to show promise, it is possible it could reach patients by the end of the decade,” Onward CEO Dave Marver said in a statement to Engadget. “It is important to note that we do not expect people with spinal cord injury to wait that long for Onward to commercialize an impactful therapy — we hope to commercialize our external spinal cord stimulation solution, ARC-EX Therapy, to restore hand and arm function in the second half of 2024.”
Onward Medical among a quickly expanding field of BCI-based startups working to apply the fledgling technology to a variety of medical maladies. Those applications include loss of limb and self-regulatory function due to stroke, traumatic brain or spinal cord injury, physical rehabilitation from those same injuries, as well as a critical means of communication for people living with Locked-In Syndrome.
Risk for community-onset C. difficile infection varies widely with choice of antibiotic.
The rising incidence of hospital-and community-acquired Clostridioides difficile infection (CDI) reinforces the need for more-effective prevention. Researchers performed a retrospective case-control study to examine relative risk for community-acquired CDI (CA-CDI) in patients receiving different oral antibiotics. Using administrative claims databases from 2001–2021 that included commercial, Medicare, and Medicaid records, they matched each CA-CDI case with five control patients for a total of 159,404 cases and 797,020 controls.
For cases occurring within 30 days of antibiotic exposure, the highest risk for CA-CDI occurred with clindamycin (adjusted odds ratio, 25.4) and the lowest with minocycline (AOR, 0.79; the only 1 of 27 oral antibiotics with an AOR 1.0). Other high-risk antibiotics were cefixime (AOR, 12.0), cefdinir (11.0), cefuroxime (9.6), cefpodoxime (9.2), amoxicillin-clavulanate (8.5), and ciprofloxacin (6.8). Older beta-lactams were lower risk (penicillin AOR, 1.8; amoxicillin, 2.0; cephalexin, 2.9; cefadroxil, 2.8). The lowest-risk antibiotic classes were the macrolides, sulfonamides, and tetracyclines. For all antibiotic classes, different agents had discernible differences in AOR for CA-CDI. A sensitivity analysis assessing relative risk for CA-CDI over multiple exposure periods up to 180 days found that the relative hierarchy of risk for the different antibiotics remained the same for each exposure period, and that overall risk progressively declined with time.
The authors acknowledge multiple limitations of their analysis, including use of administrative claims data to identify CA-CDI and outpatient claims data to identify antibiotic exposure and lack of information on inpatient antibiotic usage. Still, the large study population allowed for a more-precise definition of relative risk than in prior studies, not only showing a wide variation among beta-lactam antibiotics but also indicating that the risk associated with fluoroquinolone antibiotics falls between that of the older and newer cephalosporin classes.
